Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LYPHOMED AND VESTAR LIPOSOME COLLABORATION TO CONTINUE

Executive Summary

LYPHOMED AND VESTAR LIPOSOME COLLABORATION TO CONTINUE under a new agreement in-principle, announced Nov. 14. "All costs and profits of the joint venture will continue to be shared equally by LyphoMed and Vestar, but primary responsibilities for clinical research and marketing have been more specifically allocated between the parties," the companies stated in a joint release. Vestar, in late September, submitted a notice of termination of its original R&D agreement with LyphoMed ("The Pink Sheet" Oct. 3, T&G-5). That agreement was announced in March 1987. In September, Vestar characterized its communications with LyphoMed as "poor" and maintained that the generic injectables manufacturer had been "unwilling to hold discussions concerning the differences between the parties." The new agreement gives Vestar responsibility for clinical research on liposomal Amphotericin-B in North America and Europe. LyphoMed will be responsible for the clinical development of Amphotericin-B in Japan and for liposomal doxorubicin worldwide. Marketing responsibility for liposomal Amphotericin-B in Europe goes to Vestar and in the rest of the world to LyphoMed, which will also market the doxorubicin product worldwide. "Certain operational changes will also be made in the joint venture," the release notes.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS014642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel